ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "registry"

  • Abstract Number: 0237 • ACR Convergence 2021

    Self-perceived General Health at Start of Anti-TNF Therapy Predicts Therapeutic Response in Patients with Rheumatoid Arthritis: Analysis from the Czech Biologics Registry ATTRA

    Jakub Zavada1 and Lucie Nekvindova2, 1Institute of Rheumatology and Department of Rheumatology, First Faculty of Medicine, Charles University, Prague, Czech Republic, 2Institut biostatistiky a analýz, spin-off společnost Masarykovy univerzity, Brno, Brno, Czech Republic

    Background/Purpose: SF-36 and its components, as well as other PROs have been shown to predict various disease outcomes. We hypothesized that positive responses to questions…
  • Abstract Number: 0844 • ACR Convergence 2021

    Switching Biologics and Failure to Attain Remission in the First Year Predicts bDMARD Refractory Disease in Rheumatoid Arthritis: A 15-year Follow up of the Alberta Biologics Pharmacovigilance Cohort

    Stephanie Keeling1, Britney Jones2, Jill Hall3, Joanne Homik4, Anthony Russell1, Luck Lukusa5, Sasha Bernatsky6 and Walter Maksymowych7, 1Division of Rheumatology, University of Alberta, Edmonton, AB, Canada, 2University of Alberta/University of Calgary, Edmonton, AB, Canada, 3Faculty of Medicine and Dentistry, University of Alberta, Edmonton, AB, Canada, 4University of Alberta, Edmonton, AB, Canada, 5Research Institute of the McGill University Health Centre, Montréal, QC, Canada, 6McGill University, Montréal, QC, Canada, 7Department of Medicine, University of Alberta, Alberta, Canada, Edmonton, AB, Canada

    Background/Purpose: A subset of patients with rheumatoid arthritis (RA) experience refractory disease and do not attain remission imparting worse long-term outcomes. We evaluated RA patients…
  • Abstract Number: 0245 • ACR Convergence 2021

    Long-term Safety and Effectiveness of Abatacept Treatment in Patients with JIA: 5-year Results from the PRCSG/PRINTO JIA Real-World Registry

    Hermine Brunner1, Daniel Lovell2, Michael Henrickson1, Ruy Carrassco3, Kirsten Minden4, Lyudmila Grebenkina5, James Nocton6, Ingrid Louw7, Linda Wagner-Weiner8, Gabriel Vega Cornejo9, Sylvia Kamphuis10, Vyacheslav Chasnyk11, Heather Walters12, Simone Appenzeller13, Jordi Anton14, Alyssa Dominique15, Robert Wong16, Lixian Dong15, Tzuyung Douglas Kou15, Alberto Martini17 and Nicolino Ruperto18, 1Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 2Cincinnati Children’s Hospital Medical Center, University of Cincinnati, Cincinnati, OH, 3Presbyterian Health Services, Albuquerque, NM, 4Charite University Hospital Berlin, Berlin, Germany, 5Togliatti City Clinical Hospital №5, Togliatti, Russia, 6Medical College of Wisconsin, Milwaukee, WI, 7Panorama Medical Centre, Cape Town, South Africa, 8University of Chicago (Comer Children's), Chicago, IL, 9Crea de Guadalajara/Hospital México Americano, Guadalajara, Mexico, 10Sophia Children’s Hospital, Erasmus University Medical Center, Rotterdam, Netherlands, 11Saint-Petersburg State Pediatric Medical Academy, Saint Petersburg, Russia, 12Cohen Children's Hospital, New York, NY, 13Hospital das Clínicas da Universidade Estadual de Campinas, Campinas, Brazil, 14Hospital Sant Joan de Deu, University of Barcelona, Barcelona, Spain, 15Bristol Myers Squibb, Princeton, NJ, 16Bristol Myers Squibb, Basking Ridge, NJ, 17Paediatric Rheumatology International Trials Organisation (PRINTO), Genoa, Italy, 18IRCCS Istituto Giannina Gaslini; PRINTO, Clinica Pediatrica e Reumatologia, Genova, Italy

    Background/Purpose: Abatacept (ABA) is well tolerated and effective in patients with JIA.1 The Pediatric Rheumatology Collaborative Study Group (PRCSG)/ Paediatric Rheumatology INternational Trials Organisation (PRINTO)…
  • Abstract Number: 0853 • ACR Convergence 2021

    A Combined Patient Registry and Biobank Laboratory Information System for Prospective Multisite Chronic Rheumatic Disease Research Using REDCap

    Craig Willers1, Tom Lynch1, Vibhasha Chand2, Mohammad Islam3, Marissa Lassere4, Helen Keen5, Tony Kenna6, Susan Lester7, Ranjeny Thomas8, Premarani Sinnathurai9, Mihir Wechalekar10, Ashley Fletcher11, Daniel Lightowler12, Sheeraz Mohd13, Nishta Ramnoruth14, Carlee Ruediger15, Helen Weedon16 and Lyn March17, 1Institute of Bone and Joint Research, Kolling Institute, University of Sydney, St Leonards, Australia, 2Public Health and Preventive Medicine, Monash University, Melbourne, Australia, 3Information and Communications Technology, University of Sydney, Sydney, Australia, 4St George Hospital; School of Population Health, University of New South Wales, Carlton, Australia, 5University of Western Australia, Daglish, Australia, 6Queensland University of Technology, School of Biomedical Sciences, Brisbane, Australia, 7Rheumatology Department, The Basil Hetzel Institute, The Queen Elizabeth Hospital, Adelaide, Australia, 8University of Queensland, Diamantina Institute, Brisbane, Australia, 9Institute of Bone and Joint Research, Kolling Institute, University of Sydney; Department of Rheumatology, Royal North Shore Hospital, Northern Sydney Local Health District, Sydney, Australia, 10Flinders Medical Centre, Southern Adelaide Local Health Network, Bedford Park, Australia, 11Cabrini Health, Malvern, Australia, 12Medical School, University of Western Australia; Rheumatology Department, Fiona Stanley Hospital, Perth, Australia, 13Fiona Stanley Hospital, South Metropolitan Health Services, Perth, Australia, 14Diamantina Institute, University of Queensland, Brisbane, Australia, 15University of Adelaide; The Queen Elizabeth Hospital, Adelaide, Australia, 16Flinders University, Bedford Park, Australia, 17Institute of Bone and Joint Research, Kolling Institute, University of Sydney; Department of Rheumatology, Royal North Shore Hospital, Northern Sydney Local Health District, St Leonards, Sydney, Australia

    Background/Purpose: As we enter the big data revolution, comprehensive informatics solutions are essential to realising precision medicine for rheumatic and other chronic disease patients, especially…
  • Abstract Number: 0254 • ACR Convergence 2021

    Patient and Disease-Level Factors Associated with Sustained Cessation of Medication for Disease Remission in Systemic Juvenile Idiopathic Arthritis

    Elaine Flanagan1, Rosemary Peterson2, Susan Shenoi3, Helena Chang4, Kelly Wang4, Rebecca Trachtman4 and Karen Onel5, 1Emory/CHOA, Atlanta, GA, 2Dell Children's Medical Center, Austin, TX, 3Seattle Children's Hospital, Seattle, WA, 4Icahn School of Medicine at Mount Sinai, New York, NY, 5Hospital for Special Surgery, New York, NY

    Background/Purpose: The emergence of IL-1 and IL-6 inhibitors (biologics) for the treatment of systemic juvenile idiopathic arthritis (SJIA) has dramatically improved patient outcomes. With higher…
  • Abstract Number: 0933 • ACR Convergence 2021

    Sustained Functional Remission in Axial Spondyloarthritis (axSpA): Which Are the Primary Outcomes That Should Be Targeted to Achieve This?

    Walter Maksymowych1, Robert Inman2, Louis Bessette3, Proton Rahman4, Emmanouil Rampakakis5, Odalis Asin-Milan6, Meagan Rachich6, Anne Marilise Marrache6 and Allen Lehman6, 1Department of Medicine, University of Alberta, Alberta, Canada, Edmonton, AB, Canada, 2University Health Network, Toronto, ON, Canada, 3Centre de l'Ostoporose et de Rhumatologie de Qubec, Québec City, QC, Canada, 4Department of Medicine, Eastern Health and Memorial University of Newfoundland, St John's, NL, Canada, 5JSS Medical Research, Montréal, QC, Canada, 6Janssen Inc., Toronto, ON, Canada

    Background/Purpose: A treat-to-target (T2T) strategy has been advocated for the management of axSpA although no consensus exists as to the most appropriate target or the…
  • Abstract Number: 0255 • ACR Convergence 2021

    Identification of Tolerated Disease Activity Level for Individuals with Juvenile Idiopathic Arthritis in the Childhood Arthritis and Rheumatology Research Alliance Registry

    Melissa Mannion1, Fenglong Xie1, Timothy Beukelman1, Jeffrey Curtis2 and , for the CARRA Registry Investigators3, 1University of Alabama at Birmingham, Birmingham, AL, 2Division of Clinical Immunology and Rheumatology, Department of Medicine, Department of Epidemiology, University of Alabama at Birmingham, Birmingham, AL, 3CARRA, Durham, NC

    Background/Purpose: Recent treat to target recommendations for the treatment of juvenile idiopathic arthritis (JIA) recommend frequent evaluation and treatment intensification until the disease activity target…
  • Abstract Number: 1217 • ACR Convergence 2021

    Discontinuation Rate of Tofacitinib Is Similar When Compared to TNF Inhibitors in Rheumatoid Arthritis Patients: Pooled Data from Two Rheumatoid Arthritis Registries in Canada

    Mohammad Movahedi1, Denis Choquette2, Louis Coupal2, Angela Cesta3, Xiuying Li3, Edward Keystone4 and Claire Bombardier5, 1Toronto General Hospital Research Institute, University Health Network, Toronto, ON, Canada, 2Institut de Rhumatologie de Montréal, Montréal, QC, Canada, 3Toronto General Hospital Research Institute, UHN, Toronto, ON, Canada, 4Keystone Consulting Enterprises Inc., Toronto, ON, Canada, 5University of Toronto - Toronto, Toronto, ON, Canada

    Background/Purpose: Tofacitinib (TOFA) is an oral, small molecule drug used for rheumatoid arthritis (RA) treatment as the first or an alternative option to biologic disease-…
  • Abstract Number: 0336 • ACR Convergence 2021

    The Incremental Clinical Utility of a Multianalyte Assay Panel with Cell-Bound Complement Activation Products versus a Traditional ANA Testing Strategy for the Diagnosis and Treatment of SLE

    Tyler O'Malley1, Fenglong Xie2, yujie Su2, cassie Clinton2, Debra J. Zack1, Jeffrey Curtis3 and John Wegener1, 1Exagen Inc., Vista, CA, 2University of Alabama at Birmingham, Birmingham, AL, 3Division of Clinical Immunology and Rheumatology, Department of Medicine, Department of Epidemiology, University of Alabama at Birmingham, Birmingham, AL

    Background/Purpose: The comparative clinical utility of various diagnostic tests to aid the differential diagnosis of SLE is unclear. We compare the outcomes of testing with…
  • Abstract Number: 1264 • ACR Convergence 2021

    Racial Differences in Chronic Glucocorticoid Use in Patients with SLE: A Cross Sectional Study

    James Sullivan1 and Emily Littlejohn2, 1Cleveland Clinic Lerner College of Medicine, Cleveland Heights, OH, 2Cleveland Clinic, Cleveland, OH

    Background/Purpose: Black patients with systemic lupus erythematosus (SLE) face higher rates of morbidity and mortality compared to White patients. Long-term glucocorticoid use has been associated…
  • Abstract Number: 0354 • ACR Convergence 2021

    A Cross-Sectional Study of Rheumatoid Arthritis Diagnoses in Patients with Systemic Lupus Erythematosus

    Kathryn Starzyk1, Gary Curhan2 and Julia Brault2, 1OM1, Inc, Boston, MA, 2OM1, Boston, MA

    Background/Purpose: Features of autoimmune conditions may coexist in individual patients, which may represent an overlapping single disease with features of both (i.e., ‘rhupus’), or the…
  • Abstract Number: 1364 • ACR Convergence 2021

    Autologous Hematopoietic Stem Cell (HSC) Transplantation for Systemic Sclerosis, North American Registry: Updated Outcomes and the Impact of CD34+ HSC Enrichment

    George Georges1, Keith Sullivan2, Dinesh Khanna3, Matthew Mei4, Maureen Mayes5, Dan Furst6, Mark Wener7, Suzanne Kafaja8, Gwynn Long2, Vaishali Sanchorawala9, Kareem Jamani10, Attaphol Pawarode3, Ashish Masurekar11, Brian Lam12, Richard Nash13, Marcin Trojanowski9, Chitra Hosing14, Philip Clements15, Tanya Helms2, Bernadette McLaughlin16, Linda Griffith17, Kyle Hebert18, Mary Eapen18, Jan Storek10 and Harold Atkins11, 1Fred Hutchison Cancer Research Center and University of Washington, Seattle, WA, 2Duke University School of Medicine, Durham, NC, 3University of Michigan, Ann Arbor, MI, 4City of Hope Comprehensive Cancer Center, Duarte, CA, 5Division of Rheumatology and Clinical Immunogenetics, University of Texas McGovern Medical School, Houston, TX, 6University of California Los Angeles, Los Angeles, CA, 7University of Washington, Seattle, WA, 8University of California Los Angeles Division of Rheumatology, Los Angeles, CA, 9Boston University School of Medicine, Boston, MA, 10University of Calgary, Calgary, AB, Canada, 11Ottawa Hospital Research Institute, Ottawa, ON, Canada, 12University of Texas McGovern Medical School, Houston, TX, 13Colorado Blood Cancer Institute, Denver, CO, 14University of Texas MD Anderson Cancer Center, Houston, TX, 15University of California Los Angeles School of Medicine, Department of Rhemumatology, Los Angeles, CA, 16Fred Hutchison Cancer Research Center, Seattle, WA, 17Division of Allergy Immunology and Transplantation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, MD, 18Medical College of Wisconsin, Milwaukee, WI

    Background/Purpose: Autologous hematopoietic stem cell transplantation (AHSCT) is now established as a preferred standard of care treatment for patients with severe scleroderma with internal organ…
  • Abstract Number: 0372 • ACR Convergence 2021

    Impact of Gender and Age on Ankylosing Spondylitis Patient Profiles at Golimumab Initiation and 12-Month Outcomes

    Ariel Masetto1, Proton Rahman2, Michelle Teo3, Pauline Boulos4, Emmanouil Rampakakis5, Meagan Rachich6, Allen Lehman6, Francois Nantel7 and Odalis Asin-Milan6, 1Universite de Sherbrooke, Sherbrooke, QC, Canada, 2Department of Medicine, Eastern Health and Memorial University of Newfoundland, St John's, NL, Canada, 3Penticton Regional Hospital, Penticton, BC, Canada, 4., Hamilton, ON, Canada, 5JSS Medical Research, Montréal, QC, Canada, 6Janssen Inc., Toronto, ON, Canada, 7., Montréal, QC, Canada

    Background/Purpose: Gender and age have been previously identified as independent predictors of response to anti-TNFs. The aim of this analysis was to compare, between genders…
  • Abstract Number: 1442 • ACR Convergence 2021

    Effectiveness of Cycling JAKi Compared to Switching to bDMARD in Patients Who Failed a First JAKi in an International Collaboration of Registries of Rheumatoid Arthritis Patients (the JAK-pot Study)

    Manuel Pombo-Suarez1, Carlos Sanchez-Piedra2, Juan J Gomez-Reino3, Kim Lauper4, Nevsun Inanc5, Anja Strangfeld6, Doreen Huschek7, Karel Pavelka8, Eirik Kristianslund9, Tore Kvien10, Ziga Rotar11, Dan Nordström12, Denis Choquette13, Ori Elkayam14, Burkhard Leeb15, Maria José Santos16, Kimme Hyrich17, Lianne Kearsley-Fleet18, Catalin Codreanu19, Denis Monguin20, Delphine Courvoisier20 and Axel Finckh21, 1Rheumatology Service, Hospital Clinico Universitario, Santiago De Compostela, Santiago de Compostela, Spain, 2Research Unit, Spanish Society of Rheumatology, Madrid, Spain, 3Hospital Clínico Universitario, Santiago de Compostela, Spain, 4Geneva University Hospitals, Geneve, Switzerland, 5Division of Rheumatology, Marmara University, School of Medicine, Istanbul, Turkey, 6Deutsches Rheuma-Forschungszentrum Berlin, Berlin, Germany, 7Epidemiology and Health Services Research, German Rheumatism Research Center, Berlin, Germany, Berlin, Germany, 8Institute of Rheumatology, Department of Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic, 9Division of Rheumatology and Research, Diakonhjemmet Hospital, Oslo, Norway, Oslo, Norway, 10Diakonhjemmet Hospital, Oslo, Norway, 11Department of Rheumatology, University Medical Centre Ljubljana, Ljubljana, Slovenia and Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia, 12Division of Internal Medicine and Rheumatology, Helsinki University Hospital, Helsinki, Finland, 13Institut de Rhumatologie de Montréal, Montréal, QC, Canada, 14Tel Aviv Medical Center, Tel Aviv, Israel, 15Karl Landsteiner University for Health Sciences, Krems/Donau, Karl Landsteiner Institute for Clinical Rheumatology, Hollabrunn, Austria, 16Rheumatology Department, Hospital Garcia de Orta, Almada, Portugal, 17University of Manchester, Manchester, United Kingdom, 18Centre for Musculoskeletal Research, University of Manchester, Manchester, United Kingdom, 19Center of Rheumatic Diseases, University of Medicine and Pharmacy "Carol Davila", Bucharest, Romania, 20Division of Rheumatology, Geneva University Hospital, Geneva, Switzerland, 21University Hospital of Geneva, Geneve - Vesenaz, Switzerland

    Background/Purpose: With the arrival of new Janus kinase inhibitors (JAKi), with different JAK inhibition profiles, there is the possibility of using a second JAKi in…
  • Abstract Number: 0183 • ACR Convergence 2020

    Incidence of Malignancies in Japanese Patients with Rheumatoid Arthritis: Data from a Large Japanese National Registry

    Toshihiro Matsui1, Naonobu Sugiyama2, Tsutomu Kawaguchi2, Aosa Kamezaki2, Shigeyuki Toyoizumi3, Fujio Matsuyama4, Tatsunori Murata4, Yukitomo Urata5, Kimito Kawahata6 and Shigeto Tohma7, 1Department of Rheumatology, Clinical Research Center for Allergy and Rheumatology, National Hospital Organization Sagamihara National Hospital, Sagamihara, Japan, 2Pfizer Japan Inc, Tokyo, Japan, 3Pfizer R&D Japan G.K., Tokyo, Japan, 4CRECON Medical Assessment Inc, Tokyo, Japan, 5Department of Rheumatology, Tsugaru General Hospital, Aomori, Japan, 6Division of Rheumatology and Allergology, Department of Internal Medicine, St. Marianna University School of Medicine, Kawasaki, Japan, 7National Hospital Organization Tokyo National Hospital, Tokyo, Japan

    Background/Purpose: Patients (pts) with RA have an increased risk of some malignancies compared with the general population, and this can vary by region/race.1,2 Epidemiologic data…
  • « Previous Page
  • 1
  • …
  • 9
  • 10
  • 11
  • 12
  • 13
  • …
  • 18
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology